The new product launches, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New product launches, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Launch Trends
See who's moving and how much in your market
No credit card required Weekly product launch digest
Secretome Therapeutics unveils patents for STM-01 and STM-21 to enhance their innovative medical therapies.
Oct 28, 2024•over 1 year ago
BaltimoreBiotechnology
Product Description
Secretome Therapeutics has announced the allowance of composition of matter patents for its lead cellular therapy asset STM-01 and its secretome product STM-21. These patents will bolster the company’s intellectual property and support their upcoming Phase 1 studies for STM-01.
Company Information
Company
Secretome Therapeutics
Location
323 W Camden St, Suite 600
Baltimore, Maryland, United States
About
Secretome Therapeutics is developing a platform of first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment and prevention of underserved diseases. Our lead product, STM-21, is a novel secretome in development for adult and pediatric forms of heart failure, and our pipeline includes novel secretomes in development for neurodegenerative and dermatological diseases.
BaltimoreBiotechnology